Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Deggingen – page 11

1 295 clinical trials in Deggingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Deggingen at a glance
1 295
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 295 trials in Deggingen

Open in trial search

Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

A Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Breast neoplasm

Recruiting

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Goserelin Acetate
  • Sponsor:Eli Lilly & Co.

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Efficacy and safety of votoplam in adults with Huntington’s disease: a randomized, double‑blind, placebo‑controlled Phase 3 trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Votoplam
  • Sponsor:Novartis Pharma AG

Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 Study Comparing JNJ-79635322 with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma after 1‑3 Prior Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-79635322
  • Sponsor:Janssen Cilag International

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Neuroblastoma

Recruiting

Study of hu14.18K322A with temozolomide and irinotecan in children and adolescents with high‑risk neuroblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:hu14.18K322A
  • Sponsor:Renaissance Pharma Limited

Long‑Term Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Deggingen

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on heart failure prevention and managing atrial fibrillation, exploring new therapeutic approaches for cardiac conditions.

  • Heart Failure Prevention Studies
  • Cardioembolic Event Prevention
  • Blood Pressure Management

Research includes evaluation of novel drug combinations and preventive therapies for cardiovascular outcomes.

02 Metabolic Disorders

Comprehensive research on hypertriglyceridemia and Type 2 Diabetes Mellitus, testing new treatments for metabolic conditions.

  • Triglyceride Level Management
  • Diabetes Cardiovascular Outcomes
  • Metabolic Disease Therapies

Studies aim to improve treatment options and long-term patient outcomes in metabolic disorders.

03 Respiratory Medicine

Advanced research targeting Chronic Obstructive Pulmonary Disease, investigating new therapeutic approaches for respiratory conditions.

  • COPD Exacerbation Management
  • Respiratory Disease Treatment
  • Long-term Disease Control

Focus on reducing acute exacerbations and improving quality of life for COPD patients.

04 Other Therapeutic Areas

Studies addressing gout with hyperuricemia and various forms of hypertension, developing targeted treatments.

  • Uric Acid Management
  • Resistant Hypertension Studies
  • Long-term Safety Evaluations

Research aimed at developing effective treatments for complex medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.